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Aims Patients with heart failure and preserved ejection fraction (HFpEF) frequently have difficult-to-control hypertension.
We examined the effect of neprilysin inhibition on ‘apparent resistant hypertension’ in patients with HFpEF in the




In this post hoc analysis, patients were categorized according to systolic blood pressure at the end of the val-
sartan run-in (n = 4795). ‘Apparent resistant hypertension’ was defined as systolic blood pressure >_140 mmHg
(>_135 mmHg if diabetes) despite treatment with valsartan, a calcium channel blocker, and a diuretic. ‘Apparent
mineralocorticoid receptor antagonist (MRA)-resistant’ hypertension was defined as systolic blood pressure
>_140 mmHg (>_135 mmHg if diabetes) despite the above treatments and an MRA. The primary outcome in the
PARAGON-HF trial was a composite of total hospitalizations for heart failure and death from cardiovascular
causes. We examined clinical endpoints and the safety of sacubitril–valsartan according to the hypertension
category. We also examined reductions in blood pressure from the end of valsartan run-in to Weeks 4 and 16
after randomization. Overall, 731 patients (15.2%) had apparent resistant hypertension and 135 (2.8%) had ap-
parent MRA-resistant hypertension. The rate of the primary outcome was higher in patients with apparent re-
sistant hypertension [17.3; 95% confidence interval (CI) 15.6–19.1 per 100 person-years] compared to those
with a controlled systolic blood pressure (13.4; 12.7–14.3 per 100 person-years), with an adjusted rate ratio
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of 1.28 (95% CI 1.05–1.57). The reduction in systolic blood pressure at Weeks 4 and 16, respectively, was
greater with sacubitril–valsartan vs. valsartan in patients with apparent resistant hypertension [-4.8 (-7.0 to
-2.5) and 3.9 (-6.6 to -1.3) mmHg] and apparent MRA-resistant hypertension [-8.8 (-14.0 to -3.5) and -6.3
(-12.5 to -0.1) mmHg]. The proportion of patients with apparent resistant hypertension achieving a controlled
systolic blood pressure by Week 16 was 47.9% in the sacubitril–valsartan group and 34.3% in the valsartan
group [adjusted odds ratio (OR) 1.78, 95% CI 1.30–2.43]. In patients with apparent MRA-resistant hyperten-
sion, the respective proportions were 43.6% vs. 28.4% (adjusted OR 2.63, 95% CI 1.18–5.89).
...................................................................................................................................................................................................
Conclusion Sacubitril–valsartan may be useful in treating apparent resistant hypertension in patients with HFpEF, even in those
who continue to have an elevated blood pressure despite treatment with at least four antihypertensive drug
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Introduction
The links between hypertension and heart failure with preserved
ejection fraction (HFpEF) are well known, with left ventricular hyper-
trophy, arterial stiffening, and renal impairment likely contributing to
the development of this syndrome.1–3 Ninety percent or more of
patients with HFpEF in contemporary trials have a history of hyper-
tension.1–3 Moreover, many patients developing HFpEF remain
hypertensive and treatment of this comorbidity is one of the few rec-
ommended therapies for individuals with this heart failure pheno-
type.4,5 Recent evidence suggests that not only do many HFpEF
patients remain hypertensive but also a considerable proportion may
Graphical Abstract
Almost one in six patients with heart failure and preserved ejection fraction had apparent resistant hypertension in PARAGON-HF and this was associated
with worse clinical outcomes; neprilysin inhibition reduced systolic blood pressure significantly in these patients.
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have hypertension that is difficult to control, despite use of multiple
antihypertensive agents. Indeed, it appears that ‘resistant hyperten-
sion’ is as common in patients with HFpEF as in individuals with
hypertension more generally, with 10–20% of patients affected.6,7
Resistant hypertension is formally defined as blood pressure persist-
ently above target, despite the use of three antihypertensive agents
of different classes, including an angiotensin-converting enzyme
(ACE) inhibitor or angiotensin receptor blocker (ARB), a calcium
channel blocker, and a diuretic, although there is some variation be-
tween USA and European guidelines.8,9
Neprilysin inhibition offers an additional approach to reducing
blood pressure. Indeed, the first clinical trial using the combined
angiotensin receptor–neprilysin inhibitor, sacubitril–valsartan, was
conducted in patients with uncomplicated mild-to-moderate hyper-
tension.10 Sacubitril–valsartan 194/206 mg (LCZ696 200 mg) once
daily was compared with valsartan 320 mg once daily (the doses
selected gave equivalent plasma exposure of valsartan, due to greater
bioavailability with the combination drug). After 8 weeks of treat-
ment, sitting systolic pressure was reduced by 6.01 [95% confidence
interval (CI) -9.01 to -3.02] mmHg with sacubitril–valsartan, com-
pared with valsartan (P < 0.0001). Sacubitril–valsartan was subse-
quently developed as a treatment for heart failure using a twice
rather than once daily dosing regimen. In the first study of this agent
in patients with HFpEF, sacubitril–valsartan 97/103 mg twice daily was
compared to valsartan 160 mg twice daily in a phase 2 randomized
trial of 266 patients.11 Although change in blood pressure was not
the primary endpoint, this trial showed that, after 12 weeks of treat-
ment, sacubitril–valsartan reduced systolic pressure by 6.4 mmHg,
compared with valsartan (P = 0.001). The same treatment regimens
were then compared in a phase 3 morbidity/mortality trial in patients
with HFpEF, the Prospective Comparison of ARNI With ARB Global
Outcomes in Heart Failure With Preserved Ejection Fraction trial
(PARAGON-HF).12 Although not a hypertension trial, >95% of
patients in PARAGON-HF had a history of hypertension and, overall,
sacubitril–valsartan reduced systolic pressure by 5.2 (4.4–6.0) mmHg
compared with valsartan after 4 weeks.13 However, the effect of
sacubitril–valsartan in resistant hypertension is of special interest,
given the difficulty of controlling blood pressure in these patients and
the need for new treatments.14
The large PARAGON-HF dataset allowed post hoc exploration of
the prevalence of ‘apparent resistant hypertension’, the association
between ‘apparent resistant hypertension’ and outcomes in HFpEF,
and the effect of neprilysin inhibition on blood pressure in these
patients. We studied blood pressure control in individuals receiving
all three recommended classes of antihypertensive therapy. We also
examined a further group of patients with ‘apparent mineralocortic-
oid receptor antagonist (MRA)-resistant hypertension’ receiving, in
addition, an MRA, which has recently become the preferred fourth-
line agent as a result of the PATHWAY-2 trial.15
Methods
The design and primary results of the PARAGON-HF trial are pub-
lished.12,16,17 The ethics committee of each participating institution
approved the protocol, and all patients gave written informed consent.
Novartis is committed to sharing, with qualified external researchers,
access to patient-level data and supporting clinical documents from eli-
gible studies. These requests are reviewed and approved by an independ-
ent review panel, based on scientific merit. All data provided are
anonymized to respect the privacy of patients who have participated in
the trial in line with applicable laws and regulations. The criteria and pro-
cess for obtaining trial data are described at www.clinicalstudydatare
quest.com (last accessed 24 July 2021).
Study patients
The trial eligibility criteria included New York Heart Association
(NYHA) functional Class II–IV, a left ventricular ejection fraction (LVEF)
of 45% or higher, an elevated natriuretic peptide concentration (with the
level varying according to whether or not there had been a recent hospi-
talization for heart failure and the presence or absence of atrial fibrillation
or flutter), evidence of structural heart disease, and treatment with a diur-
etic. Exclusion criteria included systolic blood pressure >180 mmHg; in
addition, patients with a systolic blood pressure >150–180 mmHg were
excluded unless receiving at least three antihypertensive drugs. Other ex-
clusion criteria at screening included systolic blood pressure
<110 mmHg, estimated glomerular filtration rate (eGFR) <30 mL/min/
1.73 m2, and serum potassium >5.2 mmol/L.
Study treatment
Patients entered two sequential single-blind run-in periods, first receiving
valsartan 80 mg twice daily (i.e. half the target dose for heart failure and
half the maximum recommended dose for hypertension) for 1–2 weeks
and then sacubitril–valsartan 49/51 mg twice daily for 2–4 weeks. Patients
had to be free of symptoms of hypotension and have a systolic blood
pressure of at least 100 mmHg to progress through each step of the run-
in and to randomization. Participants were then randomized 1:1 to treat-
ment with either sacubitril–valsartan (target dose 97/103 mg twice daily)
or valsartan (target dose 160 mg twice daily). Valsartan 103 mg in sacubi-
tril–valsartan gives plasma exposure equivalent to 160 mg of the standard
valsartan formulation (and 51 mg the same as 80 mg).
Blood pressure measurement
Investigators were asked to measure blood pressure in the sitting pos-
ition after 5 min of rest using an automated, validated device (e.g.
OMRON) or a standard sphygmomanometer with an appropriately sized
cuff on the non-dominant arm. Investigators were also asked to ensure
patients had not taken caffeine or smoked within the 30 min preceding
the blood pressure measurement and that the measurement was made in
a quiet room, with the patient comfortably seated, back resting against
their chair.
Trial outcomes
The median follow-up duration in the PARAGON-HF trial was
35 months [interquartile range (IQR) 30–41]. The primary outcome was
a composite of first and recurrent hospitalizations for heart failure and
death from cardiovascular causes. Secondary outcomes included in this
study were the time to the first occurrence of a decline in renal function
(defined as a reduction of 50% of more in eGFR, development of end-
stage renal disease or death due to renal failure) and time to death from
any cause. We also examined the prespecified exploratory composite of
cardiovascular death, total non-fatal heart failure hospitalizations, total
non-fatal strokes and total non-fatal myocardial infarctions. Safety out-
comes analysed were hypotension (systolic blood pressure
<100 mmHg), elevation of serum creatinine, and elevation of serum po-
tassium. Because sacubitril–valsartan did not reduce the risk of the pri-
mary outcome in the trial overall, the effect of randomized therapy on
clinical outcomes was not analysed in the hypertension subgroups.

































































































A total of 4796 patients were randomized in the PARAGON-HF trial.
Inclusion, definitions, and outcomes analysed in this study are summarized
in Supplementary material online, Figure SI. In this study, the primary defin-
ition of ‘apparent resistant hypertension’ was a systolic blood pressure
>_140 mmHg (>_135 mmHg in those with diabetes) at the end of the val-
sartan run-in, despite concomitant treatment with a calcium channel
blocker and diuretic (thiazide or thiazide-like, loop, or potassium-sparing
other than an MRA), as well as valsartan.12,16,17 Concomitant medications
were at the start of the run-in period, i.e. prior to the visit at which the pa-
tient was defined as having resistant hypertension. An alternative defin-
ition was also used in supplementary analyses: systolic blood pressure
>_130 mmHg at the end of valsartan run-in despite concomitant treat-
ment with a calcium channel blocker and diuretic, as well as valsartan,
reflecting the American Heart Association recommendations.8 Finally, we
also examined patients with more refractory, ‘apparent MRA-resistant’
hypertension, defined as: systolic blood pressure >_140 mmHg
(>_135 mmHg in those with diabetes) at the end of valsartan run-in, des-
pite concomitant treatment with a calcium channel blocker, diuretic and
an MRA, as well as valsartan (i.e. at least four classes of blood pressure-
lowering therapy, including an MRA). Other patients were considered to
have non-resistant hypertension if systolic blood pressure remained
above the respective thresholds, but the definition of apparent resistant
hypertension was not fulfilled (i.e. patients were not on the specified
blood pressure-lowering drug combination) and considered to have a
‘controlled blood pressure’ if systolic blood pressure was below the re-
spective thresholds at the end of the valsartan run-in (irrespective of con-
comitant medications and accepting that many of these patients had
effectively treated hypertension). Baseline characteristics were compared
using t-tests, ANOVA, Wilcoxon rank-sum test, and v2 tests where ap-
propriate. Reduction in systolic blood pressure from the end of the val-
sartan run-in to Weeks 4 and 16 after randomization, on sacubitril–
valsartan vs. valsartan, was analysed using a mixed model for repeated
measures (including all values up to Week 16, including baseline value and
interaction of treatment and visit with a random intercept and slope per
patient), and the between treatment group differences at Week 16 fol-
lowing randomization were presented as least square means difference
and 95% CI. In the event of death prior to Week 16, blood pressure
measurements were included up until the time at which the death
occurred and were recorded as missing thereafter. The proportion of
patients with controlled systolic blood pressure at 16 weeks, defined as
reduction in systolic blood pressure to below 140 mmHg in patients with-
out diabetes and to below 135 mmHg in patients with diabetes (and as a
reduction in systolic blood pressure to below 130 mmHg using the alter-
native definition of apparent resistant hypertension), was examined and
the odds of a reduction were estimated using logistic regression. The pri-
mary composite outcome and one of its components, total heart failure
hospitalizations, were examined using a semiparametric proportional
rates method.18 Cardiovascular death, all-cause death, and the renal out-
come were examined using Cox proportional hazards regression.
Cumulative first events were displayed using Kaplan–Meier curves. The
Nelson-Aalen non-parametric estimator for cumulative hazard rate func-
tion, which accounts for patients who are censored due to competing
events (i.e. cardiovascular death), was used to display the hazard of recur-
rent events. The proportional hazards assumptions were checked and
met for all models. All models examining the primary and secondary trial
outcomes included randomized treatment and were stratified by region.
The multivariable models for the primary and secondary trial outcomes
also included sex, age, heart rate, body mass index, N-terminal pro-B-
type natriuretic peptide (NT-proBNP) (log), NYHA class, LVEF, eGFR,
prior hospitalization for heart failure, myocardial infarction, diabetes,
cigarette smoking history (current or former), and atrial fibrillation. Safety
outcomes were compared across the hypertension categories using a lo-
gistic regression model, adjusted for region, with a test for interaction.
Multivariable models for systolic blood pressure change included age,
sex, body mass index, cigarette smoking history (current or former), and
region. All analyses were conducted using STATA version 16 (StataCorp
LLC, College Station, TX, USA). A P-value of <0.05 was considered statis-
tically significant.
Results
One patient without a recorded systolic blood pressure measure-
ment at the end of the valsartan run-in period was excluded. Of the
4795 patients included, 731 (15.2%) had apparent resistant hyperten-
sion, 1268 (26.4%) had hypertension that was not resistant, and 2796
(58.3%) had a controlled blood pressure. A total of 135 patients
(2.8%) had apparent MRA-resistant hypertension. The mean (stand-
ard deviation) systolic blood pressures at the end of the valsartan
run-in in patients with apparent resistant hypertension, non-resistant
hypertension, and a controlled blood pressure were 149.2 (±11.0),
149.1 (±11.2), and 123.6 (±9.2) mmHg, respectively. Systolic blood
pressure in patients with apparent MRA-resistant hypertension was
148.0 (±9.7) mmHg. Data on patients with apparent resistant hyper-
tension using the alternative definition are given in Supplementary
material online, Table SI.
We examined adherence to randomized therapy, as measured by
pill count, and persistence with non-randomized blood pressure-
lowering therapy. Adherence to sacubitril–valsartan and valsartan
was high throughout the trial. The mean total daily doses of blood
pressure-lowering therapies are presented in Table 1, and doses of
calcium channel blocker and MRA were similar at 6 months and
1 year after randomization. At the final visit, target dose of the study
drug was reached in 87.4% of patients with apparent resistant hyper-
tension who were continuing therapy and was similar irrespective of
randomized group. At 6 months and 1 year, a calcium channel blocker
was prescribed in 88.3% and 86.7% of patients with apparent resistant
hypertension and any diuretic in 95.7% and 95.0%, respectively. The
study drug was discontinued in 25.4% of patients with apparent re-
sistant hypertension for reasons other than death.
Patient characteristics
Patients with apparent resistant hypertension were more often White
and less often Asian and had a higher body mass index and eGFR, com-
pared to patients with a controlled blood pressure, although all these
differences were small (Table 1). Patients with apparent resistant
hypertension were much more likely to have diabetes (60.5% vs.
35.6%) but had a lower median NT-proBNP level (744 vs. 962 pg/mL)
than those with a controlled blood pressure (Table 1). Patients with
apparent resistant hypertension were more often treated with a diur-
etic, calcium channel blocker and alpha-blocker than those with a con-
trolled blood pressure but less often treated with an MRA. Age,
NYHA class distribution, and the proportions of patients with a prior
heart failure hospitalization or stroke were similar, irrespective of
hypertension category. The distribution of baseline characteristics was
similar in patients meeting the alternative definition of apparent resist-
ant hypertension (Supplementary material online, Table SI).
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Systolic blood pressurea (mmHg) 123.6 ± 9.2 149.1 ± 11.2 149.2 ± 11.0 <0.001 <0.001 <0.001
Diastolic blood pressurea (mmHg) 72.7 ± 10.0 80.4 ± 10.5 78.7 ± 10.7 <0.001 <0.001 <0.001
Pulse pressurea (mmHg) 50.9 ± 10.6 68.7 ± 14.0 70.5 ± 14.2 <0.001 <0.001 <0.001
Age (years) 72.6 ± 8.5 73.2 ± 8.4 72.5 ± 8.2 0.11 0.058 0.68
Women 1419 (50.8) 689 (54.3) 370 (50.6) 0.09 0.034 0.95
Race <0.001 0.052 <0.001
American Indian/Alaska native 27 (1.0) 18 (1.4) 6 (0.8)
Asian 414 (14.8) 145 (11.4) 48 (6.6)
Black/African American 59 (2.1) 24 (1.9) 19 (2.6)
Native Hawaiian/Pacific Islander 1 (0.0) 0 (0.0) 0 (0.0)
Other 69 (2.5) 37 (2.9) 22 (3.0)
White 2226 (79.6) 1044 (82.3) 636 (87.0)
Cigarette smoking
(current or former)
1106 (39.9) 472 (37.4) 276 (37.8) 0.27 0.14 0.31
Left ventricular ejection
fraction (%)
57.6 ± 8.0 57.3 ± 7.9 57.6 ± 7.5 0.36 0.17 1.00
Heart rate (b.p.m.) 70.7 ± 12.3 70.6 ± 12.3 69.2 ± 11.9 0.010 0.88 0.003
Body mass index (kg/m2) 30.0 ± 5.0 30.2 ± 5.1 31.2 ± 4.8 <0.001 0.32 <0.001
Body mass index (>30 kg/m2) 1320 (47.2) 611 (48.2) 422 (57.7) <0.001 0.55 <0.001
eGFR (mL/min/1.73 m2) 62 ± 19 64 ± 19 63 ± 20 0.019 0.005 0.34
eGFR (<60 mL/min/1.73 m2) 1400 (50.1) 579 (45.7) 362 (49.5) 0.033 0.010 0.79
NT-proBNP (pg/mL) 962 (488–1625) 847 (458–1606) 744 (408–1560) <0.001 0.026 <0.001
NYHA class 0.76 0.40 0.95
I 75 (2.7) 40 (3.2) 22 (3.0)
II 2152 (77.0) 990 (78.1) 563 (77.0)
III 557 (19.9) 231 (18.2) 144 (19.7)
IV 10 (0.4) 7 (0.6) 2 (0.3)
Diabetes 996 (35.6) 623 (49.1) 442 (60.5) <0.001 <0.001 <0.001
Prior heart failure hospitalization 1350 (48.3) 614 (48.4) 341 (46.6) 0.70 0.93 0.43
Stroke 290 (10.4) 127 (10.0) 91 (12.4) 0.20 0.71 0.11
Calcium channel blocker 867 (31.0) 49 (3.9) 731 (100.0) <0.001 <0.001 <0.001
Total daily amlodipine-
equivalent doseb
6.9 ± 2.9 7.4 ± 2.6 7.4 ± 3.2 0.015 0.34 0.004
Thiazide or thiazide-like diuretic 572 (20.5) 257 (20.3) 195 (26.7) <0.001 0.89 <0.001
Loop diuretic 2192 (78.4) 950 (74.9) 609 (83.3) <0.001 0.014 0.003
Mineralocorticoid receptor
antagonist
858 (30.7) 300 (23.7) 135 (18.5) <0.001 <0.001 <0.001
Total daily doseb 27.5 ± 13.8 27.0 ± 13.5 30.4 ± 17.2 0.06 0.61 0.032
Other potassium-sparing diuretic 37 (1.3) 15 (1.2) 9 (1.2) 0.93 0.71 0.85
Beta-blocker 2236 (80.0) 1033 (81.5) 564 (77.2) 0.07 0.27 0.094
Total daily bisoprolol-
equivalent doseb
4.9 ± 3.3 4.9 ± 3.0 5.1 ± 3.1 0.46 0.70 0.31
Alpha-blockerc 148 (5.3) 99 (7.8) 95 (13.0) <0.001 0.002 <0.001
Data are presented as mean ± standard deviation or median (interquartile range) for continuous measures and n (%) for categorical measures. Medications are at the run-in.
Global P-value is for the comparison of all three groups.
BP, blood pressure; eGFR, estimated glomerular filtration rate; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association.
aAt the end of valsartan run-in.
bIn patients taking the drug, amlodipine-equivalent dose is calculated for amlodipine, felodipine, and lercanidipine; bisoprolol-equivalent dose is calculated for bisoprolol, aten-
olol, metoprolol, carvedilol, and nebivolol; and mineralocorticoid receptor antagonist dose is calculated for spironolactone and eplerenone.
cDoxazosin, prazosin, bunazosin, terazosin, naftopidil, or urapidil.

































..Patients with apparent MRA-resistant hypertension were younger,
had a higher body mass index, lower natriuretic peptide level, and
more often had a diabetes than patients with a controlled blood pres-
sure (Supplementary material online, Table SII). Patients with appar-
ent MRA-resistant hypertension were more often treated with a
diuretic, calcium channel blocker and alpha-blocker than those with a
controlled blood pressure.
Outcomes according to hypertension
category
The rate of the primary composite outcome was higher in
patients with apparent resistant hypertension (17.3; 95% CI 15.6–
19.1 per 100 person-years) compared to those with a controlled
blood pressure (13.4; 12.7–14.3 per 100 person-years), with
an adjusted rate ratio of 1.28 (95% CI 1.05–1.57) (Table 2 and
Figure 1). The greater risk of the primary composite outcome in
patients with apparent resistant hypertension was driven by a
higher rate of heart failure hospitalization whereas the risk of
death from cardiovascular causes (and from any cause) was not
different between these groups.
The rate of the prespecified exploratory composite outcome of
cardiovascular death, total heart failure hospitalizations, total strokes,
and total myocardial infarctions was also higher in patients with
apparent resistant hypertension (20.8; 95% CI 19.0–22.8 per 100
person-years) compared to those with a controlled blood pressure
(16.3; 95% CI 15.4–17.2 per 100 person-years), with an adjusted rate
ratio of 1.30 (95% CI 1.08–1.55).
The risk of the composite renal outcome was significantly higher in
patients with apparent resistant hypertension (1.2; 95% CI 0.8–1.7
per 100 person-years) compared to those with a controlled blood
pressure (0.6; 95% CI 0.4–0.8 per 100 person-years), with an adjusted
rate ratio of 1.72 (95% CI 1.04–2.86).
....................................................................................................................................................................................................................
Table 2 Outcomes according to hypertension category referent to patients without controlled blood pressure
Controlled blood
pressure (n 5 2796)
Non-resistant
hypertension (n 5 1268)
Apparent resistant
hypertension (n 5 731)
Primary outcome
Number of events 1078 455 370
Event rate (95% CI) 13.4 (12.7–14.3) 12.4 (11.3–13.6) 17.3 (15.6–19.1)
Unadjusted rate ratio (95% CI) 1.00 1.00 (0.84–1.18) 1.35 (1.10–1.67)
Adjusted rate ratio (95% CI) 1.00 0.93 (0.78–1.09) 1.28 (1.05–1.57)
Total HF hospitalizations
Number of events 818 353 316
Event rate (95% CI) 10.2 (9.5–10.9) 9.6 (8.6–10.6) 14.7 (13.2–16.5)
Unadjusted rate ratio (95% CI) 1.00 1.03 (0.86–1.25) 1.53 (1.21–1.93)
Adjusted rate ratio (95% CI) 1.00 0.96 (0.79–1.15) 1.42 (1.14–1.78)
CV death, total HF hospitalizations, MIs, strokes
Number of events 1305 603 446
Event rate (95% CI) 16.3 (15.4–17.2) 16.4 (15.1–17.8) 20.8 (19.0–22.8)
Unadjusted rate ratio (95% CI) 1.00 1.09 (0.94–1.26) 1.35 (1.12–1.63)
Adjusted rate ratio (95% CI) 1.00 1.02 (0.88–1.19) 1.30 (1.08–1.55)
CV death
Number of events 260 102 54
Event rate (95% CI) 3.2 (2.9–3.7) 2.8 (2.3–3.4) 2.5 (1.9–3.3)
Unadjusted hazard ratio (95% CI) 1.00 0.88 (0.70–1.11) 0.80 (0.60–1.08)
Adjusted hazard ratio (95% CI) 1.00 0.83 (0.66–1.05) 0.81 (0.60–1.10)
Death from any cause
Number of events 414 180 97
Event rate (95% CI) 5.2 (4.7–5.7) 4.9 (4.2–5.7) 4.5 (3.7–5.5)
Unadjusted hazard ratio (95% CI) 1.00 0.96 (0.80–1.14) 0.89 (0.71–1.11)
Adjusted hazard ratio (95% CI) 1.00 0.90 (0.75–1.08) 0.89 (0.70–1.12)
Renal outcome
Number of events 45 27 25
Event rate (95% CI) 0.6 (0.4–0.8) 0.7 (0.5–1.1) 1.2 (0.8–1.7)
Unadjusted hazard ratio (95% CI) 1.00 1.38 (0.86–2.24) 2.19 (1.34–3.58)
Adjusted hazard ratio (95% CI) 1.00 1.19 (0.73–1.94) 1.72 (1.04–2.86)
Unadjusted models include randomized treatment and are stratified by region. Adjusted models include randomized treatment, sex, age, heart rate, body mass index, N-termin-
al pro-B-type natriuretic peptide (log), New York Heart Association class, left ventricular ejection fraction, estimated glomerular filtration rate, prior hospitalization for HF, MI,
diabetes, cigarette smoking, and atrial fibrillation, and are stratified by region. Rates are per 100 person-years.
CI, confidence interval; CV, cardiovascular; HF, heart failure; MI, myocardial infarction.








































..The rate of all the outcomes of interest was similar in patients
with non-resistant hypertension and those with a controlled blood
pressure (Table 2 and Figure 1).
A broadly similar pattern was seen using the alternative definition
of apparent resistant hypertension (Supplementary material online,
Table SIII and Figure SII) and in apparent MRA-resistant hypertension,
although the relatively small number of patients in the latter group
precluded formal analysis of outcomes (Supplementary material
online, Table SIV and Figure SIII).
Effect of sacubitril–valsartan (compared
with valsartan) on systolic blood pressure
in patients with resistant hypertension
Systolic blood pressure declined between the end of the valsartan
80 mg b.i.d. run-in period and the end of the subsequent sacubitril–
valsartan 49/51 mg b.i.d. run-in period, in all three groups of patients
without a controlled blood pressure (Table 3 and Figure 2). After
randomization, blood pressure remained lower in patients assigned
to 97/103 mg of sacubitril–valsartan b.i.d. In those assigned to valsar-
tan 160 mg b.i.d., systolic blood pressure rose above the level at
the randomization visit but remained below the level at the end of
the valsartan 80 mg b.i.d. run-in period (Table 3 and Figure 2).
As a result, systolic blood pressure was reduced more by sacubitril–
valsartan (97/103 mg b.i.d.) than by valsartan (160 mg b.i.d.) at both 4
and 16 weeks after randomization, compared to the end of valsartan
run-in, in patients with apparent resistant hypertension (Table 3 and
Figure 2), with differences between the treatment groups of -4.8 (-7.0
to -2.5) mmHg at Week 4 and -3.9 (-6.6 to -1.3) mmHg at Week 16.
In patients with apparent MRA-resistant hypertension, the
absolute reduction in systolic blood pressure was also larger with
sacubitril–valsartan, compared with valsartan: -8.8 (-14.0 to -3.5)
mmHg and -6.3 (-12.5 to -0.1) mmHg at Weeks 4 and 16, respective-
ly (Table 3 and Figure 2).
Proportion of patients with resistant
hypertension achieving systolic blood
pressure control with sacubitril–
valsartan (compared with valsartan)
The proportion of patients with apparent resistant hypertension
achieving a controlled systolic blood pressure by Week 16 was
Figure 1 Hazard and survival curves according to hypertension category. (A) Primary outcome. (B) Total heart failure hospitalizations. (C)
Cardiovascular death, total heart failure hospitalizations, strokes, and myocardial infarctions. (D) Cardiovascular death. BP, blood pressure; CV, cardio-
vascular; HF, heart failure; MI, myocardial infarction.


















































..significantly greater in participants assigned to sacubitril–valsartan
(47.9%) than in those assigned to valsartan (34.3%), with an adjusted
odds ratio (OR) of 1.78 (95% CI 1.30–2.43) (Table 3).
The relative proportion of responders was greatest in patients
with apparent MRA-resistant hypertension (43.6% vs. 28.4%), with
an adjusted OR of 2.63 (95% CI 1.18–5.89).
Safety and tolerability of sacubitril–
valsartan in patients with resistant
hypertension
Hypotension was more common with sacubitril–valsartan than with
valsartan, although the excess in patients with apparent resistant
hypertension was small (Table 4). Conversely, elevation of serum cre-
atinine and potassium was less common with sacubitril–valsartan
than with valsartan, in patients with apparent resistant hypertension.
The pattern of adverse events was broadly similar using the alterna-
tive definition of apparent resistant hypertension and in those with
apparent MRA-resistant hypertension (Supplementary material on-
line, Tables SV and SVI).
Discussion
As defined in this study, ‘apparent resistant hypertension’ was com-
mon in patients with HFpEF, affecting 15% of all individuals at the end
of the valsartan run-in period in PARAGON-HF (and 37% of those
whose systolic blood pressure remained elevated at that time point).
Patients with ‘apparent resistant hypertension’, as defined in this
study, had a greater risk of the primary composite of hospitalization
for heart failure and cardiovascular death and the prespecified ex-
ploratory composite of hospitalization for heart failure, myocardial
infarction, stroke, and cardiovascular death. When added to an ARB
(valsartan), a calcium channel blocker, and a diuretic (and even to
these three agents plus an MRA), neprilysin inhibition lowered systol-
ic blood pressure significantly and increased the proportion of
patients with controlled hypertension (Graphical abstract). Given the
overall safety profile of sacubitril–valsartan, compared with valsartan,
and better renal function, switching from an ACE inhibitor or ARB to
sacubitril–valsartan may offer an effective and safe approach to con-
trolling resistant hypertension in patients with HFpEF. This possibility
merits further investigation in prospective hypertension trial with a
more rigorous definition of resistant hypertension.
Although HFpEF is widely recognized as a hypertensive phenotype,
little is known about the prevalence of hypertension in HFpEF and
how best to lower blood pressure in patients with this syndrome.1–5
In a pooled analysis (n = 8466) of the three largest morbidity/mortal-
ity trials in HFpEF before PARAGON-HF, 46% of participants had a
systolic blood pressure >_140 mmHg (or >_135 mmHg in individuals
with diabetes) and 70% a systolic blood pressure >_130 mmHg, indi-
cating that hypertension remains a highly prevalent and sub-optimally
treated problem in these patients.19 In terms of therapy, diuretics
are often needed to control sodium and water retention in HFpEF,
making them a first-line treatment for comorbid hypertension. While
ARBs did not improve HFpEF outcomes in two large randomized
...................................... ...................................... ...................................... ...........................................
....................................................................................................................................................................................................................
Table 3 Changes in systolic blood pressure and blood pressure control in patients with ‘non-resistant’, ‘apparent re-

















SBP at end of valsartan
run-in (mmHg)
123.9 ± 9.1 123.3 ± 9.2 149.4 ± 11.1 148.8 ± 11.3 149.4 ± 11.0 148.9 ± 11.1 148.1 ± 9.8 148.0 ± 9.5
Change from end of
valsartan run-in to
Week 4
þ3.6 ± 0.4 -0.4 ± 0.4 -6.0 ± 0.7 -12.3 ± 0.6 -6.6 ± 0.8 -11.4 ± 0.8 -3.6 ± 1.7 -12.4 ± 2.0
Between treatment
group difference
-4.0 (-5.0 to -3.0) -6.2 (-8.0 to -4.4) -4.8 (-7.0 to -2.5) -8.8 (-14.0 to -3.5)
Change from end of
valsartan run-in to
Week 16
þ4.9 ± 0.4 þ0.8 ± 0.4 -7.0 ± 0.8 -10.9 ± 0.7 -6.4 ± 0.9 -10.3 ± 1.0 -2.8 ± 2.1 -9.1 ± 2.4
Between treatment
group difference
-4.1 (-5.3 to -2.9) -3.9 (-6.0 to -1.8) -3.9 (-6.6 to -1.3) -6.3 (-12.5 to -0.1)
SBP controlled by
Week 16, n (%)
964 (71.1) 1103 (81.7) 216 (37.5) 304 (47.5) 127 (34.3) 163 (47.9) 21 (28.4) 24 (43.6)
Adjusted odds ratio
(95% CI) for SBP
control
1.80 (1.49–2.16) 1.52 (1.20–1.92) 1.78 (1.30–2.43) 2.63 (1.18–5.89)
SBP is shown as mean ± standard deviation and changes are shown as estimate ± standard error. All models include SBP at the end of valsartan run-in, age, sex, body mass index,
cigarette smoking, and region. Models examining SBP change also include SBP at all other time points up to Week 16 and an interaction term between treatment and time.
CI, confidence interval; MRA, mineralocorticoid receptor antagonist; SBP; systolic blood pressure.
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Figure 2 Change in systolic blood pressure in patients with controlled blood pressure, ‘non-resistant’, ‘apparent resistant’, and ‘apparent mineralo-
corticoid receptor antagonist-resistant’ hypertension. Week -2 = end of the open run-in period of treatment with valsartan 80 mg twice daily and
Week 0 = end of the open run-in period of treatment with sacubitril–valsartan 49/51 mg, Thereafter, patients randomized to double-blind treatment
with valsartan 160 mg twice daily or sacubitril–valsartan 97/103 mg twice daily. Models include systolic blood pressure at the end of the valsartan
run-in, age, sex, body mass index, cigarette smoking, and region, as well as systolic blood pressure at all other time points up to Week 16 and an inter-
action term between treatment and time. MRA, mineralocorticoid receptor antagonist.
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Hypotension 208 (14.8) 314 (22.5) 38 (6.2) 50 (7.6) 11 (2.9) 16 (4.5) 0.55
Elevated serum creatinine (mg/dL)
>_2.0 185 (13.2) 146 (10.5) 69 (11.3) 64 (9.7) 74 (19.5) 51 (14.5) 0.71
>_2.5 51 (3.6) 54 (3.9) 27 (4.4) 21 (3.2) 31 (8.2) 22 (6.2) 0.41
>_3.0 18 (1.3) 26 (1.9) 9 (1.5) 6 (0.9) 13 (3.4) 6 (1.7) 0.09
Elevated serum potassium (mmol/L)
>5.5 217 (15.5) 187 (13.4) 77 (12.6) 77 (11.7) 67 (17.7) 51 (14.5) 0.87
>6.0 59 (4.2) 42 (3.0) 21 (3.4) 19 (2.9) 21 (5.5) 14 (4.0) 0.91

































































































controlled morbidity/mortality trials,20,21 these studies did not raise
safety concerns and ARBs are, therefore, another useful antihyper-
tensive therapy in HFpEF. The same is true of spironolactone.22
Thereafter, evidence is lacking. There is no large randomized
placebo-controlled experience with beta-blockers, with only 314
patients with an LVEF >_50% enrolled in the landmark trials, and a re-
cent analysis of non-randomized beta-blocker use in TOPCAT
showed that this treatment was associated with a higher risk of heart
failure hospitalization in patients with an LVEF >_50%.23,24
Dihydropyridine calcium channel blockers cause peripheral oedema
and heart failure to develop significantly more often in hypertensive
patients treated with alpha-adrenoceptor blockers than with other
blood pressure-lowering drugs.25 Indeed, in the setting of increased
pulmonary blood flow, dihydropyridine calcium channel blockers can
cause pulmonary oedema as a result of pre-capillary vasodilation in
the pulmonary circulation, and it is of interest that the two blood
pressure groups with the highest rates of use of calcium channel
blockers (controlled blood pressure and apparent resistant hyper-
tension) had the highest rates of heart failure hospitalization in the
present study.26 The possibility that neprilysin inhibition might be an
effective, as well as safe, blood pressure-reducing therapy in HFpEF
suggests that this approach may be a valuable addition to the antihy-
pertensive options available for these patients (and consistent with
early studies of sacubitril and sacubitril–valsartan in patients with un-
complicated hypertension, including elderly individuals who comprise
the majority of people with HFpEF).10,13,27,28
However, the focus of the current report is ‘apparent resistant
hypertension’, and neprilysin inhibition also reduced blood pressure
in patients remaining hypertensive despite treatment with the recom-
mended combination of an ARB, a calcium channel blocker, and a di-
uretic; indeed, 77% of these patients were also treated with a beta-
blocker and 13% with an alpha-blocker. Spironolactone has also been
shown to reduce blood pressure in HFpEF patients with resistant
hypertension. Specifically, in TOPCAT, 403 HFpEF patients (23%)
enrolled in the Americas had ‘resistant hypertension’, defined as a
systolic blood pressure between 140 and 160 mmHg, despite treat-
ment with three or more antihypertensive medications.6 After
4 months, systolic blood pressure was reduced by 5.53 (standard
error 1.95) mmHg with spironolactone compared with placebo, in
keeping with the superior blood pressure reduction exhibited with
spironolactone, compared with other treatments, in patients with re-
sistant hypertension in the PATHWAY-2 trial.15 In TOPCAT, spir-
onolactone also increased the proportion of patients achieving blood
pressure control significantly (OR 1.77, 95% CI 1.16–2.69).6 In our
analysis of the 731 patients in PARAGON-HF qualifying because of a
similar blood pressure threshold, neprilysin inhibition reduced systol-
ic blood pressure by 3.9 (-6.6 to -1.3) mmHg at 4 months. Neprilysin
inhibition also increased the proportion of patients with a controlled
blood pressure significantly (OR 1.78, 95% CI 1.30–2.43). More im-
portantly, neprilysin inhibition also reduced systolic blood pressure
[by 6.3 (-12.5 to -0.1) mmHg] in the 135 patients treated with an
MRA in addition to an ARB, a calcium channel blocker, and a diuretic
(i.e. with at least four drugs), resulting in a more than doubling of the
proportion of patients attaining blood pressure control with neprily-
sin inhibition (OR 2.63, 95% CI 1.18–5.89). Given the superior effi-
cacy of spironolactone as a treatment for resistant hypertension, and
the high risk faced by these patients, we believe that this incremental
antihypertensive action of neprilysin inhibition on top of an MRA
could be of considerable clinical importance, if confirmed. This
benefit is likely to reflect the complementary and additive mecha-
nisms of action of the two drugs, with spironolactone treating so-
dium and water retention and neprilysin inhibition augmenting
natriuretic and other vasodilator peptides (e.g. adrenomedullin),
as well as possibly reducing sympathetic activation.29 The eleva-
tion in natriuretic peptides may be particularly relevant in this pa-
tient subgroup who had the lowest baseline levels of these
peptides, probably reflecting the high prevalence of obesity in
these patients.30–32 In addition to more effective blood pressure
lowering, sacubitril–valsartan reduces arterial stiffness and left
ventricular mass more than an ARB, other actions likely to be
valuable in patients with HFpEF.33,34
Importantly, the renal safety profile of sacubitril–valsartan in this
study was favourable, irrespective of the definition of resistant hyper-
tension used. In fact, elevation of serum creatinine and potassium
generally occurred less frequently in patients with apparent resistant
hypertension taking sacubitril–valsartan than it did in those taking val-
sartan. This is particularly important in patients taking both an ARB
and MRA, where the risk of decline in renal function and/or hyperka-
laemia is accentuated.35,36
Examining clinical outcomes, it was of interest that patents with
‘non-resistant’ hypertension were at lower risk than patients with ‘ap-
parent resistant hypertension’, despite a similar baseline systolic
blood pressure and, in fact, had a risk similar to patients with a con-
trolled blood pressure. The greater risk of the primary composite
outcome seen for patients with ‘apparent resistant hypertension’ was
driven predominantly by heart failure hospitalization, consistent with
heart failure being a blood pressure sensitive endpoint in hyperten-
sion trials. We do not know what the explanation for this is, although
our data suggest several possibilities. The prevalence of obesity was
higher in the ‘apparent resistant hypertension’ group, compared with
both the ‘non-resistant’ hypertension and controlled blood pressure
groups (who had a similar prevalence of obesity) and more obese
HFpEF patients have higher heart failure hospitalization rates.37
Baseline use of an MRA was lowest in patients with apparent resistant
hypertension and highest in those with a controlled blood pressure
group, and MRA therapy may reduce the risk of heart failure hospital-
ization in HFpEF.23 Conversely, the use of alpha-adrenoceptor antag-
onists was much higher among patients with apparent resistant
hypertension than in the other groups, and alpha-blockers increase
the risk of heart failure hospitalization in patients with hypertension.25
It is possible that there were other differences between these groups
for which we did not have data. For example, patients with apparent
resistant hypertension may have had a longer history of disease, a lon-
ger time sub-optimally treated in the early course of their disease, un-
identified end-organ damage, or differences in diurnal blood pressure
profile.
Two additional observations are worthy of comment, although are
not based on randomized comparisons. First, the decline in systolic
blood pressure after switching from valsartan 80 mg b.i.d. to sacubi-
tril–valsartan 49/51 mg b.i.d. (i.e. from the first to the second con-
secutive run-in period) seemed to be larger than the blood pressure
difference between valsartan 80 and 160 mg b.i.d. However, systolic
pressure did appear to decrease with 160 mg b.i.d. of valsartan com-
pared to 80 mg b.i.d. of valsartan.

































































































This study had some limitations. Certain patients were excluded
from PARAGON-HF including those with a systolic blood pressure
>180 mmHg and an eGFR <30 mL/min/1.73 m2. Similarly, patients
with a systolic blood pressure of >150 and <180 mmHg were only
eligible for enrolment if receiving at least three antihypertensive
agents, which may have increased the proportion of patients who ful-
filled the definition of apparent resistant hypertension in this study.
Blood pressure measured at trial follow-up visits was not standar-
dized and repeated in the same way as in dedicated hypertension tri-
als and we did not perform ambulatory blood pressure monitoring
or out-of-office measurements, which would be required to confirm
true resistant hypertension. We did not have information on treat-
ment adherence or time between administration of antihypertensive
medication and measurements of blood pressure, but drug adher-
ence in patients with heart failure has previously been found to be
much better than in people with hypertension.38–40 Because of the
way we measured blood pressure, because we did not know the
doses of all classes of blood pressure-lowering drugs or whether
these were at maximally tolerated doses, and because we could not
confirm adherence, we could not exclude pseudo-resistance; there-
fore, the term ‘apparent resistant hypertension’ was used to describe
this group, although the proportion of patients in this category was
consistent with other studies of patients classified as having resistant
hypertension. Also, as our trial had sequential run-in periods, the
patients randomized to valsartan 160 mg b.i.d. had just discontinued
sacubitril–valsartan 49/51 mg b.i.d. As the effect of sacubitril–valsartan
was borderline statistical significance in the overall trial, we did not
have the power to examine the effect of sacubitril–valsartan in each
hypertension subgroup.
In summary, we have examined the efficacy and safety of sacubi-
tril–valsartan in treating apparent resistant hypertension in patients
with HFpEF, when compared with valsartan alone. Our findings sug-
gest that sacubitril–valsartan is effective in reducing blood pressure
not only in patients with apparent resistant hypertension but also in
those who have more refractory, or apparent MRA-resistant hyper-
tension, with an elevated systolic blood pressure despite treatment
with at least four antihypertensive drug classes, including an MRA.
Supplementary material
Supplementary material is available at European Heart Journal online.
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10. Ruilope LM, Dukat A, Böhm M, Lacourcière Y, Gong J, Lefkowitz MP. Blood-
pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin
II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active
comparator study. Lancet 2010;375:1255–1266.
11. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V,
Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJ; Prospective
comparison of ARNI with ARB on Management Of heart failUre with preserved
ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprily-
sin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2
double-blind randomised controlled trial. Lancet 2012;380:1387–1395.
12. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F,
Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ,
Zannad F, Zile MR, Desai AS, Claggett B, Jhund PS, Boytsov SA, Comin-Colet J,
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